Signals, Powered By EquityPandit
Rohto Pharmaceutical which is a Japanese firm, has been planning to expand its base in India with SastaSundar Heathbuddly Ltd as its preferred partner.
Raj Juneja, Rohto Executive VP and Global Head of International Business said that “We are looking for expansion of our base in India with SastaSundar as our preferred partner. We have invested USD 5 million (Rs 32 crore) to acquire 13 percent stake in SastaSundar.”
He further said that, Rohto will be able to expand its presence in India utilising the network of SastaSundar.
